TransMedics Receives FDA Conditional IDE Approval to Initiate OCS ENHANCE Heart Study

Shots: TransMedics received US FDA conditional IDE approval to initiate its two-part Next‑Gen OCS ENHANCE Heart study evaluating prolonged heart perfusion (Part A) and superiority of OCS Heart in donation after brain death (DBD) cases vs static cold storage (Part B) The study will enroll >650 pts; Part B aims to expand OCS Heart indications…

ByPrince GiriAugust 6, 2025

INSIGHTS+

Top Performing Drug – Trikafta/Kaftrio (May Edition)

Shots: In continuation of our previous series on the top-performing drug of the month, based on 2021 revenue, this month we have covered Trikafta/Kaftrio as the top-performing drug of the month Trikafta is a combination of ivacaftor, tezacaftor, and elexacaftor indicated for the treatment of cystic fibrosis in pediatric patients who have at least one…

BySenior EditorMay 24, 2023

TransMedics Receives FDA Conditional IDE Approval to Initiate OCS ENHANCE Heart Study

Top Performing Drug – Trikafta/Kaftrio (May Edition)

Contact US

OUR INFORMATION

FOLLOW US